Dr. Steven Gray
Clinical Senior Lecturer, Clinical Medicine
Clinical Senior Lecturer, Molecular Medicine Ireland
Biography
Steven Gray graduated from Trinity College Dublin in 1992. He joined the laboratory of Tomas J. Ekstrom at the Karolinska Institute in 1996 and received his PhD in 2000 (Thesis Title: The IGF-axis in liver disease: Modulation of expression by histone deacetylase inhibitors). He moved to the Van Andel Research Institute in Michigan, USA where he continued his studies on the therapeutic potential of histone deacetylase inhibitors in the treatment of cancer. He also spent some time as a visting fellow at Harvard Medical School, Boston working on epigenetic therapies for neurodegenerative disease. Returning to Europe Dr Gray spent some time at the German Cancer Research Centre (DKFZ - Heidelberg), and subsequently moved to Copenhagen to work for Novo Nordisk as part of the research team of Prof Pierre De Meyts at the Hagedorn Research Institute working on epigenetic mechanisms underpinning diabetes pathogenesis. Dr Gray is currently a senior clinical scientist at St James's Hospital in the Deprtment of Clinical Oncology at the Thoraacic Oncology Research Group at St. James's Hospital headed by Dr. Sinead Cuffe and Professor Stephen Finn, and holds an adjunct assistant professorship with the Dept of Clinical Medicine (TCD).
Publications and Further Research Outputs
Peer-Reviewed Publications
Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, Krstic-Demonacos M, Markel G, Giordano A, Bomze D, Mutti L., Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma., JAMA Netw Open, 5, (3), 2022, pe221490
Perryman L, Gray SG., Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases. , Cancers, 14, (4), 2022, p981
Sui JSY, Finn SP, Gray SG., Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach., Methods in molecular biology (Clifton, N.J.), 2279, 2021, p145-155
Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, Kantarci AG, Finn SP., Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids., Journal of nanobiotechnology, 19, (71), 2021, p1-20
MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Gray SG, Reidy M, Nicholson S, Leonard N, Ryan R, Young V, O'Leary JJ, Cuffe S, Finn SP, O'Byrne KJ, Barr MP., MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer., Translational lung cancer research, 10, (4), 2021, p1773-1791
MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin., Translational Oncology, 14, (4), 2021, p101025-
Baird AM, Finn SP, Gray SG, Sheils O., Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16, (1), 2021, p14-16
Gray SG., Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma., BMC pulmonary medicine, 21, (1), 2021, p148
Porta C, Nardone V, Gray SG, Correale P, Mutti L., RAMES study: is there really a role for VEGF inhibition in mesothelioma?, The Lancet. Oncology, 22, (12), 2021, pe532
Lim MCJ, Baird AM, Greene J, McNevin C, Ronan K, Podlesniy P, Sheils O, Gray SG, McDermott RS, Finn SP., hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. , Cancers, 13, (24), 2021, p6383
John Greene, Anne-Marie Baird, Marvin Lim, Joshua Flynn, Ciara McNevin, Lauren Brady, Orla Sheils, Steven G Gray, Raymond McDermott, Stephen P Finn, Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer, Frontiers in cell and developmental biology, 9, 2021, p334-
Burgess JT, Bolderson E, Adams MN, Duijf PHG, Zhang SD, Gray SG, Wright G, Richard DJ, O'Byrne KJ., SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer., Scientific reports, 10, (1), 2020, p18605
Sui JSY, Martin P, Gray SG., Pre-clinical models of small cell lung cancer and the validation of therapeutic targets., Expert opinion on therapeutic targets, 24, (3), 2020, p187-204
Chellamuthu A, Gray SG., The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer. , Cells, 9, (8), 2020, pE1758
Gray SG, Mutti L., Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives., Translational lung cancer research, 9, (suppl 1), 2020, pS100-S119
Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA; European Thoracic Oncology Platform Lungscape Consortium., Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort., Modern Pathology, 33, (5), 2020, p792 - 801
Ryan, S.-L. and Beard, S. and Barr, M.P. and Umezawa, K. and Heavey, S. and Godwin, P. and Gray, S.G. and Cormican, D. and Finn, S.P. and Gately, K.A. and Davies, A.M. and Thompson, E.W. and Richard, D.J. and O'Byrne, K.J. and Adams, M.N. and Baird, A.-M., Targeting NF-KB-mediated inflammatory pathways in cisplatin-resistant NSCLC, Lung Cancer, 135, 2019, p217-227
Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG., When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?, Frontiers in endocrinology, 10, 2019, p89
Felley-Bosco E, Gray SG., Mesothelioma Driver Genes, Ferroptosis, and Therapy., Frontiers in oncology, 9, 2019, p1318
Zhao J, Gray S.G, Greene C.M, Lawless M.W, Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer, Expert Review of Gastroenterology and Hepatology, 13, (3), 2019, p247 - 256
Kerr K.M, Thunnissen E, Dafni U, Finn S.P, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E.-J.M, Pokharel S, Quinn A.M, Monkhorst K, Navarro A, Madsen L.B, Radonic T, Wilson J, De Luca G, Gray S.G, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans A.-M, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R, A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project, Lung Cancer, 131, 2019, p95 - 103
Gray SG., Squaring the circle: sponging microRNAs in gastric cancer., Translational cancer research, 8, (suppl 2), 2019, pS183-S187
Mohamed BM, Boyle NT, Schinwald A, Murer B, Ward R, Mahfoud OK, Rakovich T, Crosbie-Staunton K, Gray SG, Donaldson K, Volkov Y, Prina-Mello A., Induction of protein citrullination and auto-antibodies production in murine exposed to nickel nanomaterials., Scientific Reports, 8, (679), 2018
MacDonagh, L. and Gray, S.G. and Breen, E. and Cuffe, S. and Finn, S.P. and O'Byrne, K.J. and Barr, M.P., BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC, Cancer Letters, 428, 2018, p117-126
Letovanec, I. and Finn, S. and Zygoura, P. and Smyth, P. and Soltermann, A. and Bubendorf, L. and Speel, E.-J. and Marchetti, A. and Nonaka, D. and Monkhorst, K. and Hager, H. and Martorell, M. and Sejda, A. and Cheney, R. and Hernandez-Losa, J. and Verbeken, E. and Weder, W. and Savic, S. and Di Lorito, A. and Navarro, A. and Felip, E. and Warth, A. and Baas, P. and Meldgaard, P. and Blackhall, F. and Dingemans, A.-M. and Dienemann, H. and Dziadziuszko, R. and Vansteenkiste, J. and O'Brien, C. and Geiger, T. and Sherlock, J. and Schageman, J. and Dafni, U. and Kammler, R. and Kerr, K. and Thunnissen, E. and Stahel, R. and Peters, S. and Stahel, R.A. and Rosell, R. and Blackhall, F. and Dafni, U. and Kerr, K.M. and Molina, M.Ã . and Bubendorf, L. and Weder, W. and Thunnissen, E. and Peters, S. and Finn, S. and Hiltbrunner, A. and Kammler, R. and Geiger, T. and Marti, N. and Dafni, U. and Tsourti, Z. and Polydoropoulou, V. and Zygoura, P. and Finn, S. and Smyth, P. and O'Brien, C. and Gray, S. and Weder, W. and Soltermann, A. and Opitz, I. and Curioni, A. and Bubendorf, L. and Savic, S. and Lardinois, D. and Dingemans, A.-M. and Speel, E.-J.M. and Ruland, A. and Marchetti, A. and Di Lorito, A. and De Luca, G. and Malatesta, S. and Blackhall, F. and Nonaka, D. and Quinn, A.M. and Franklin, L. and Biernat, W. and Wrona, A. and Rzyman, W. and Jassem, J. and Meldgaard, P. and Hager, H. and Madsen, L.B. and Camps, C. and Martorell, M. and Jantus-Lewintre, E. and Guijarro, R. and Kerr, K.M. and Nicolson, M. and Stevenson, D.A.J. and Mathieson, W. and Baas, P. and de Jong, J. and Monkhorst, K. and Thunnissen, E. and Smit, E. and van Setten, C. and de Langen, J. and Felip, E. and Hernandez-Losa, J. and Sansano, I. and Cheney, R. and Pine, M.B. and Reid, M. and Taylor, E. and Nackaerts, K. and Dooms, C. and Wauters, E. and Van Der Borght, S. and Dienemann, H. and Muley, T. and Warth, A., Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project, Journal of Thoracic Oncology, 13, (3), 2018, pe33-e34
Dockry É, O'Leary S, Gleeson LE, Lyons J, Keane J, Gray SG, Doherty DG, Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells, OncoImmunology, 2018, pe1428156-
Gray S.G, We're Stressed Out: BET-Ting on Oxidative Stress?, BioEssays, 40, (5), 2018
Singh, A.S. and Heery, R. and Gray, S.G., In silico and in vitro analyses of lncRNAs as potential regulators in the transition from the epithelioid to sarcomatoid histotype of malignant pleural mesothelioma (MPM), International Journal of Molecular Sciences, 19, (5), 2018, p1297-
John Aird, Anne-Marie Baird, Marvin C.J. Lim, Ray McDermott, Stephen P. Finn, Steven G. Gray, Carcinogenesis in prostate cancer: The role of long non-coding RNAs, Non-coding RNA Research, 3, (1), 2018, p29--38
Quinn Leah, Gray Steven G, Meaney Steve, Finn Stephen, McLoughlin Padraig, Hayes Maria, Extraction and Quantification of Sinapinic Acid from Irish Rapeseed Meal and Assessment of Angiotensin-I Converting Enzyme (ACE-I) Inhibitory Activity , Journal of agricultural and food chemistry , 65 , (32 ), 2017, p6886 - 6892
Greene John, Baird Anne-Marie, Brady Lauren, Lim Marvin, Gray Steven G, McDermott Raymond, Finn Stephen P, Circular RNAs: Biogenesis, Function and Role in Human Diseases , Frontiers in molecular biosciences , 4 , 2017, p38 -
Gray, S.G. and Wright, M.C. and Finn, S.P., The "eyes" have it?-intra- and inter-observer reproducibility of the PD-L1 companion diagnostic assay, Translational Cancer Research, 6, 2017, pS1027-S1029
Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O'Byrne K.J, Cuffe S, Finn S.P, Gray S.G, Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma, International Journal of Oncology, 50, (3), 2017, p1044 - 1052
Heery Richard, Finn Stephen P, Cuffe Sinead, Gray Steven G, Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells , Cancers , 9 , (4 ), 2017, p38-
Baird AM, Gray SG, Richard DJ, O'Byrne KJ, Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model., Scientific reports, 6, 2016, p18907
MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, Lung cancer stem cells: The root of resistance., Cancer letters, 372, (2), 2016, p147-56
Gray, S.G., Cuffe, S., Finn, S.P., PD-L1 as a companion biomarker for immune checkpoint inhibitors in NSCLC: Should RNA ISH (RISH) be considered?, Journal of Thoracic Oncology, 11, (11), 2016, e142-e144
Joerger, M., Finn, S.P., Cuffe, S., Byrne, A.T., Gray, S.G., The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?, Expert Opinion on Therapeutic Targets, 20, (11), 2016, 1339-1356
Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG, KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma., International journal of oncology, 48, (3), 2016, p1290-6
Perry AS, Baird AM, Gray SG, Epigenetic Methodologies for the Study of Celiac Disease., Methods in molecular biology (Clifton, N.J.), 1326, 2015, p131-58
MacDonagh,Lauren , Gray,Steven George, Finn,Stephen P. , Cuffe,Sinead D. , O'Byrne,Kenneth John, Barr,Martin P. , The emerging role of microRNAs in resistance to lung cancer treatments, Cancer Treatment Reviews, 41, (2), 2015, p160-169
Introduction in, editor(s)Steven G. Gray , Epigenetic Cancer Therapy, 1st Edition, Academic Press, 2015, pp1 - 6, [Steven G. Gray]
Chapter 26. Epigenetics of Cisplatin Resistance. in, editor(s)Stevn G. Gray , Epigenetic Cancer Therapy, 1st Edition. , Academic Press, 2015, pp613 - 637, [Steven G. Gray]
Quinn L, Finn SP, Cuffe S, Gray SG, Non-coding RNA repertoires in malignant pleural mesothelioma., Lung cancer (Amsterdam, Netherlands), 90, (3), 2015, p417-26
Barr, M.P., Gray, S.G., Gately, K., (...), Pidgeon, G.P., O'Byrne, K.J., Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer, Molecular Cancer, 14, (1), 2015, p45-
Chapter 9. Epigenetic Therapy in Lung Cancer and Mesothelioma in, editor(s)Steven G. Gray , Epigenetic Cancer Therapy, 1st Edition. , Academic Press, 2015, pp189 - 213, [Anne-Marie Baird, Derek Richard, Kenneth J. O'Byrne, Steven G. Gray]
Zhao, Jun , Greene, Catherine M. , Gray, Steven George , Lawless, Matthew William, Long noncoding RNAs in liver cancer: What we know in 2014, Expert Opinion on Therapeutic Targets, 18, (10), 2014, p1207-1218
Gray,Steven George S.G., Epigenetic-based immune intervention for rheumatic diseases, Epigenomics, 6, (2), 2014, p253-271
Gray,Steven George S.G., Perspectives on epigenetic-based immune intervention for rheumatic diseases, Arthritis Research and Therapy, 15, (2), 2013, p207
Baird AM, Leonard J, Naicker KM, Kilmartin L, O'Byrne KJ, Gray SG, IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer., Lung cancer (Amsterdam, Netherlands), 79, (1), 2013, p83-90
Wright CM, Kirschner MB, Cheng YY, O'Byrne KJ, Gray SG, Schelch K, Hoda MA, Klebe S, McCaughan B, van Zandwijk N, Reid G, Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM)., PloS one, 8, (8), 2013, pe70940
Versteyhe S, Klaproth B, Borup R, Palsgaard J, Jensen M, Gray SG, De Meyts P, IGF-I, IGF-II, and Insulin Stimulate Different Gene Expression Responses through Binding to the IGF-I Receptor., Frontiers in endocrinology, 4, 2013, p98
Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ., Generation and characterisation of Cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature., PloS one, 8, (1), 2013, pe54193
Baird AM, O'Byrne KJ, Gray SG, Epigenetic regulation of chemokine/chemokine receptor expression., Methods in molecular biology (Clifton, N.J.), 1013, 2013, p185-201
Baird AM, Dockry E, Daly A, Stack E, Doherty DG, O'Byrne KJ, Gray SG, IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer., Frontiers in oncology, 3, 2013, p162-
Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, Gray SG, O'Byrne KJ, Fennell DA, Vacca RA, Nilsson S, Mutti L, Moro L, Estrogen receptor ß activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo., Oncogenesis, 2, 2013, pe72
Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, Bueno R, Sugarbaker DJ, Fennell DA, Broaddus VC, Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression., PloS one, 7, (12), 2012, pe52753
Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, McLaughlin KM, Busacca S, Barbone D, Broaddus VC, Gray SG, O'Byrne KJ, Johnston PG, Fennell DA, Longley DB, Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent., European journal of cancer (Oxford, England : 1990), 48, (7), 2012, p1096-107
Busacca S, Sheaff M, Arthur K, Gray SG, O'Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP, Quinn JE, Fennell DA, BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma., The Journal of pathology, 227, (2), 2012, p200-8
Allott EH, Oliver E, Lysaght J, Gray SG, Reynolds JV, Roche HM, Pidgeon GP, The SGBS cell strain as a model for the in vitro study of obesity and cancer., Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 14, (10), 2012, p774-82
Gray SG, Baird AM, O'Kelly F, Nikolaidis G, Almgren M, Meunier A, Dockry E, Hollywood D, Ekström TJ, Perry AS, O'Byrne KJ, Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor., International journal of molecular medicine, 30, (6), 2012, p1505-11
Baird AM, Gray SG, O'Byrne KJ, IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF., European journal of cancer (Oxford, England : 1990), 47, (12), 2011, p1908-18
Baird, AM; Gray, SG; O'Byrne, KJ , Expression of the CXC (ELR plus ) receptor, CXCR2, is reactivated by epigenetic means in non-small cell lung cancer, Lung Cancer, 71, 2011
Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC, Receptor tyrosine kinases and their activation in melanoma., Pigment Cell & Melanoma Research, 24, (3), 2011, p446-461
Anne-Marie Baird, Steven G. Gray, Kenneth J. O'Byrne, Epigenetics Underpinning the Regulation of the CXC (ELR+) Chemokines in Non-Small Cell Lung Cancer, PLoS One, 6, (1), 2011, pe14593
KJ O'Byrne, The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer, Cancers , 3, (1), 2011, p1426-1453
Easty, D., Gray, S.G., Baird, A., Soltermann, A., Nonaka, D., Fennell, D.A., Opitz, I., Pass, H.I., Mutti, L., O'Donnell, D.M., and O'Byrne, K.J. , MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma, Journal of Clinical Oncology, 29, 2011
O'Byrne KJ, Barr MP, Gray SG., The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer, Cancers, 3, (1), 2011, p1426 - 1453
Gray SG, Epigenetic treatment of neurological disease., Epigenomics, 3, (4), 2011, p431-50
Busacca, S., Gray, S.G., Paul, I., McTavish, N., O'Byrne, K.J., Quinn, J.E., and Fennell, D.A. , BRCA1 expression and efficacy of vinorelbine in malignant mesothelioma, Journal of Clinical Oncology, 29, 2011
Kenneth J. O'Byrne ; Anne-Marie Baird ; Lisa Kilmartin ; Jennifer Leonard ; Calen Sacevich ; Steven G. Gray, Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer, Cancers , 3, (2), 2011, p1550-1565
Gray, S.G., Easty, D., Baird, A., Soltermann, A., Nonaka, D., Fennell, D.A., Mutti, L., Pass, H.I., Opitz, I., O'Donnell, D., and O'Byrne, K.J. , The Macrophage Stimulating Protein (MSP)-RON/MST1R axis in malignant pleural mesothelioma, IASLC World Lung , Amsterdam, Netherlands , July 3-7, 2011, 2011
Cathcart MC, Gray SG, Baird AM, Boyle E, Gately K, Kay E, Cummins R, Pidgeon GP, O'Byrne KJ, Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer., Cancer, 117, (22), 2011, p5121-32
Lawless, MW, Norris, S, O'Byrne, KJ, Gray, SG, Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders., Endocrine, metabolic & Immune Disorders Drug Targets, 9, (1), 2009, p84-107
Lawless, M. W., Norris, S., O'Byrne, K.J. and Gray, S.G., Histone Deacetylase inhibitors for the treatment of disease, Journal of Cellular and Molecular Medicine, 2009
Histone deacetylase inhibitors as a therapeutic modality in multiple sclerosis in, editor(s)Dr. Serena Guiducci & Dr Moncef Zouali , The Epigenetics of Autoimmune Diseases, Wiley Press, 2009, pp403 - 432, [Gray, S.G.]
Krunic, D., Moshir, S., Greulich-Bode, K.M., Figueroa, R., Cerezo, A., Stammer, H., Stark, H.-J., (...), Boukamp, P., Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss , Biochimica et Biophysica Acta - Molecular Basis of Disease, 1792, (4), 2009, p297-308
Mankan, A.K., Lawless, M.W., Gray, S.G., Kelleher, D., McManus, R., NF-κB regulation: The nuclear response , Journal of Cellular and Molecular Medicine , 13, (4), 2009, p631-643
Gray, SG, Fennell, DA, Mutti, L, O'Byrne, KJ, In arrayed ranks: array technology in the study of mesothelioma., Journal of Thoracic Oncology : official publication of the International Association for the Study of Lung Cancer, 4, (3), 2009, p411-425
Mahmood, S., Borup, R., Gray, S.G., and De Meyts, P., Gene expression profiling of human adipocyte responses to insulin and IGF-I signalling., The Open Diabetes Journal, 2, 2009, p5-17
Gray, S.G., Crowe, J., Lawless, M.W., Hemochromatosis: As a conformational disorder , International Journal of Biochemistry and Cell Biology , 2009
Lawless, MW, Norris, S, O'Byrne, KJ, Gray, SG, "Targeting Histone Deacetylases for the treatment of disease", Journal of cellular and molecular medicine, 2008
Lawless, MW, Mankan, AK, Gray, SG, Norris, S, Endoplasmic reticulum stress--a double edged sword for Z alpha-1 antitrypsin deficiency hepatoxicity., The international journal of biochemistry & cell biology, 40, (8), 2008, p1403-1414
Gray, SG, Al-Sarraf, N, Baird, AM, Gately, K, McGovern, E, O'Byrne, KJ, Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells., Clinical lung cancer, 9, (6), 2008, p367-374
Lawless, M., Norris, S., O'Byrne, K.J and Gray, S.G., Targeting epigenetic pathways in obesity and diabetes, Cellscience Reviews, 4, (3), 2008, p119-166
Al-Sarraf, N, Reiff, JN, Hinrichsen, J, Mahmood, S, Teh, BT, McGovern, E, De Meyts, P, O'byrne, KJ, Gray, SG, DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma., International journal of cancer. Journal international du cancer, 121, (5), 2007, p992-998
Gray, S.G. , DMMC workshop: unravelling chromatin and the role of epigenetics in disease., Epigenetics : official journal of the DNA Methylation Society, 1, (4), 2006, p187-189
Gray, S.G., and Dangond, F. , Rationale for the Use of Histone Deacetylase Inhibitors as a Therapeutic Modality in Multiple Sclerosis, Epigenetics, 1, (2 I), 2006, p67-75
Villanueva, R., Iglesias, A., Camelo, S., Sanin, L.C. Gray, S.G. and Dangond, F. , Histone deacetylase 3 represses HTLV-1 tax transcription. , Oncology Reports, 16, (3), 2006, p581-585
Greulich-Bode, K.M., Moshir, S., Figueroa, R., Cerezo, A., Lindenmaier, H., Stark, H-J., Gray, S.G., Vang Nilsen, K., Hartschuh, W., and Boukamp, P. , Differential Regulation of Telomere Length and Telomerase Activity in Normal Skin Keratinocytes In Vivo and In Vitro, 2006
"Malignant pleural mesothelioma: clinical presentation, radiological evaluation and diagnosis" in, editor(s)Kenneth O'Byrne, Consultant Oncologist, Hope Directorate, St James's Hospital, Dublin, Ireland Valerie Rusch, Chief of the Thoracic Service Surgery, William G Cahan Chair, Memorial Sloan-Kettering Cancer Center, New York, USA , Malignant Pleural Mesothelioma , Great Clarendon Street, Oxford OX2 6DP, Oxford University Press, 2006, pp35 - 60, [Michael D. Peake, James Entwisle, and Steven Gray]
Shaukat Mahmood, Steven G. Gray, Rehannah Borup, Martin Wabitsch, Hans E. Tornqvist, Pierre De Meyts, Gene expression profiling of adipocyte/preadipocyte responses to Insulin and IGF-I signalling, Systems Biology: Integrating Biology, Technology and Computation (C6), Taos, New Mexico, USA, 05/03/06 - 10/03/06, 2006
Gray, SG, Dangond, F, Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis., Epigenetics : official journal of the DNA Methylation Society, 1, (2), 2006, p67-75
Gray S.G., Iglesias AH, Lizcano F, Villanueva R, Camelo S, Jingu H, Teh BT, Koibuchi N, Chin WW, Kokkotou E, Dangond F. , Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein., Journal of Biological Chemistry, 280, (31), 2005, p28507 - 28518
Takahashi, M., Gray, S.G., Yuhas, J., Qian, C-N., Kanayama, H., Kagawa, S., Teh, B.T., Altered expression of members of the IGF-axis in Renal Cell Carcinoma, International Journal of Oncology, 26, (4), 2005, p923 - 931
Gray, S.G. and De Meyts, P., Role of histone and transcription factor acetylation in diabetes pathogenesis, Diabetes and Metabolism Research and Reviews, 21, (5), 2005, p416 - 433
Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ, Dangond F, Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis., Journal of Neuroimmunology, 164, (1-2), 2005, p10 - 21
Gray, S.G. , Erratum: The Insulin-like Growth Factors and Insulin-signalling Systems: An Appealing Target for Breast Cancer Therapy (Hormone and Metabolic Research (2003) 35 (857-871)) , Hormone and Metabolic Research, 36, (1), 2004, p74
Gray, S.G., Qian, C-N., Furge, K., Guo, X. and Teh, B.T., Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines, International Journal of Oncology, 24, (4), 2004, p773 - 795
Histone Acetyltransferases and Histone Deacetylases in Gene Regulation and as Drug Targets in, editor(s)Vincent T. DeVita, Jr., M.D. Samuel Hellman, M.D. Steven A. Rosenberg, M.D., Ph.D. , Progress in Oncology, USA, Jones and Bartlett , 2004, pp99 - 128, [Gray, S.G.]
Gray, S.G., Mathiasen, I.S., and De Meyts, P.D, The Insulin-like Growth Factors and Insulin-signalling Systems: An Appealing Target for Breast Cancer Therapy?, Hormone and Metabolic Research, 35, (11-12), 2003, p857 - 871
Takahashi, M., Yang, X. J., Sugimura, J., Backdahl, J., Tretiakova, M., Qian, C-N., Gray, S. G., Knapp, R., Anema, J., Kahnoski, R., Nicol, D., Vogelzang, N. J., Furge, K. A., Kanayama, H., Kagawa, S., Teh, B. T. , Molecular sub-classification of kidney cancers and the discovery of new diagnostic markers, Oncogene, 22, (43), 2003, p6810 - 6818
Gray, S.G., Iglesias, A., Teh, B.T., and Dangond, F., Modulation of Splicing Events in Histone Deacetylase 3 by various Extracellular and Signal Transduction Pathways, Gene Expression, 11, (1), 2003, p13 - 21
Svechnikova, I., Gray, S. G., Kundrotiene, J., Ponthan, F., Kogner, P. and Ekström, T. J., Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate, International Journal of Oncology, 22, 2003, p579 - 588
von Horn, H., Hwa, V., Rosenfeld, R. G., Hall, K., Teh, B. T., Tally, M., Ekström, T.J., and Gray, S.G. , Altered expression of low affinity insulin-like growth factor binding protein related proteins in hepatoblastomas, International Journal of Molecular Medicine, 9, (6), 2002, p645 - 649
Guo, X., Lui, W-O., Qian, C-N., Chen, J-D., Gray, S.G., Rhodes, D., Haab, B., Stanbridge, E., Wang, H., Hong, M-H., Min, H-Q., Larsson, C., and Teh, B.T., Identifying cancer-related genes in nasopharyngeal carcinoma cell lines using DNA and mRNA expression profiling analyses, International Journal of Oncology, 21, 2002, p1197 - 1204
Gray, S.G. and Teh, B. T., Histone Acetylation/Deacetylation and cancer: An "open" and "shut" case?, Current Molecular Medicine, 1, (4), 2001, p401 - 429
Dangond, F., Henriksson, M., Zardo, G., Caiafa, P. Ekström, T.J.,and Gray, S.G., Differential expression of class I HDACs: roles of cell density and cell cycle, International Journal of Oncology, 19, (4), 2001, p773 - 777
Gray, S.G. and Ekström T. J., The Human Histone Deacetylase Family, Experimental Cell Research, 262, 2001, p75 - 83
Eriksson, T., Frisk, T., Gray, S.G., von Schweinitz, D., Pietsch, T., Larsson, C., Sandstedt, B. and Ekström, T.J., Methylation Changes in the Human IGF2 P3 Promoter Parallel IGF2 Expression in the Primary Tumor, Established Cell Line, and Xenograft of a Human Hepatoblastoma , Experimental Cell Research, 270, (1), 2001, p88 - 95
Hartmann, W., Waha, A., Koch, A., Gray, S.G., Ekström, T.J., von Schweinitz, D., and Pietsch, T., Promoter-specific transcription of the IGF2 gene: a novel rapid, non-radioactive and highly sensitive protocol for mRNA analysis, Virchows Archiv, 439, 2001, p803 - 807
Gray, S.G., Guo, X., Kedra, D., Min, H-Q., and Teh, B.T., Correspondence re: P.P. Claudio et al., Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma, Cancer Research, 61, (15), 2001, p6950 - 6952
von Horn, H., Tally, M., Hall, K., Ekström, T.J., and Gray, S.G., Expression levels of insulin-like growth factor binding proteins and insulin receptor isoforms in hepatoblastomas, Cancer Letters, 162, (2), 2001, p253 - 260
Gray, S.G., Svechnikova, I., Hartmann, W., Aguilar-Santileses, M. and Ekström, T.J., IGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with Trichostatin A, Cytokine, 12, (7), 2000, p1104 - 1109
Gray, S.G., Kytölä, S., Matsunaga, T., Larsson, C. and Ekström, T.J. , Comparative genomic hybridization reveals population based genetic alterations in hepatoblastomas, British Journal of Cancer, 83, 2000, p1020 - 1025
Gray, S.G., Kytölä, S., Weng O L., Larsson, C., and Ekström, T.J., Modulating IGFBP-3 expression by Trichostatin A: Potential therapeutic role in the treatment of Hepatocellular carcinoma, International Journal of Molecular Medicine, 5, (1), 2000, p33 - 41
Gray, S.G., Hartman, W., Kytölä, S., Eriksson, T., Ekström, C., von Schweinitz, D., Kogner, P., Sandstedt, B., Larsson, C., Pietsch, T., and Ekström, T.J., Expression of genes involved with cell cycle control, cell growth and chromatin modification are altered in hepatoblastomas, International Journal of Molecular Medicine, 6, 2000, p161 - 169
Gray, S.G., Eriksson, T., Ekström, C., Holm, S., Von Schweinitz, D., Kogner, P., Sandstedt, B., (...), Ekström, T.J. , Altered expression of members of the IGF-axis in hepatoblastomas, British Journal of Cancer , 82, (9), 2000, p1561-1567
Gray, S.G., Eriksson, E., and Ekström, T.J., Methylation, gene expression and the chromatin connection in cancer, International Journal of Molecular Medicine, 4, (4), 1999, p333 - 350
Gray, S.G., Yakovleva, T., Hartmann, W., Tally, M., Bakalkin, G., and Ekström, T.J., IGF-II enhances trichostatin A-induced TGFβ1 and p21(Waf1/Cip1/Sdi1) expression in Hep3B cells, Experimental Cell research, 253, (2), 1999, p618 - 628
Wang, Y., Rea, T., Bian, J., Gray, S., Sun, Y. , Identification of the genes responsive to etoposide-induced apoptosis: Application of DNA chip technology, FEBS Letters , 445, (2-3), 1999, p269-273
Kjellman, M., Roshani, L., Teh, B.T., Kallioniemi, O-P., Höög, A., Gray, S., Farnebo, L-O., Holst, M., Bäckdahl, M., and Larsson, C., Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1 cM region in 2p16., The Journal of clinical endocrinology and metabolism, 84, (2), 1999, p730 - 735
Li, X., Gray, S.G., Flam, F., Pietsch, T., and Ekström, T. J., Developmental-dependent DNA methylation of the IGF2 and H19 promoters is correlated to the promoter activities in human liver development, International Journal of Developmental Biology, 42, (5), 1998, p687 - 693
Betz, R., Gray, S.G., Larsson, C., and Ekström, T. J. , Human Histone Deacetylase 2, HDAC2 (hRPD3), is located to 6q21 by Radiation Hybrid Mapping, Genomics, 52, 1998, p245 - 246
Gray, S.G., and Ekström, T. J., Effects of Cell Density and TrichostatinA on the Expression of HDAC1 and p57Kip2 in Hep 3B Cells, Biochemical and Biophysical Research Communications, 245, (2), 1998, p423 - 427
Gray, S.G., Kjellman, M., Larsson, C., and Ekström, T. J., Novel splicing of an IGF2 polymorphic region in human adrenocortical carcinomas, Biochemical and Biophysical Research Communications, 239, (3), 1997, p878 - 883
Research Expertise
Description
My research mainly involves using epigenetic targeting agents to examine fundamental mechanisms underpinning the regulation of (i) Receptor Tyrosine Kinases (RTKs); (ii) inflammation and (iii) cellular metabolism in thoracic malignancy and to study their potential therapeutic efficacy in the treatment of lung cancer and mesothelioma. Research in my laboratory also tries to understand the role of epigenetics and epigenetic mechanisms underpinning drug resistance in lung cancer and mesothelioma. In addition to the above my research also involves the study of non-coding RNA repertoires (lncRNAs and circRNAs) in lung cancer and mesothelioma for their potential utility as candidate biomarkers for the early prediction of thoracic malignancy, and to study their roles in lung cancer biogenesis and resistance to therapy.Recognition
Representations
Steering Committee Mesothelioma Research Network Steering Group (UK) (2018 - 2022)
Senior Board Member BMC Pulmonary Medicine
Section Editor: Clinical Epigenetics (https://clinicalepigeneticsjournal.biomedcentral.com/about/editorial-board)
Associate Editor Molecular and Structural Endocrinology (specialty section of Frontiers in Endocrinology)
Associate Editor: BMC Cancer
Associate Editor: PLoS One
Editorial Board: International Journal of Oncology
Editorial Board: Cancers (MDPI)
Editorial Board: Cells (MDPI)
Grant reviewer Australian National Health and Medical Research Council (NHMRC) (2010, 2012, 2017) Austrian Science Fund (2011, 2019) Bulgarian Science Foundation (2008) British Lung Foundation (2010, 2020) Cancer Research UK (2009) Czech Science Foundation (2012) Cyprus Research Promotion Foundation (2011) The Dutch Organisation for Health Research and Development (ZonMw) (2017) The Eli and Edythe Broad Foundation - Broad Medical Research Program (2012) Enterprise Ireland Commercialisation Fund (2005, 2006, 2008) Eureka Eurostars Technical Experts (2015-2020) EU - H2020-Marie Skłodowska-Curie Actions (Reviewer -2020, 2021 ; Rapporteur, 2021) Fondation contre le Cancer - Belgium (2016) Fondazione Pisa - Italy (2016) Fondazione Regionale Per La Ricerca Biomedica [Lomardy Region] (2020, 2022) France's National Research Agency -ANR [Agence Nationale de la Recherche] (2008, 2011) German Research Foundation (2009)
Grant Reviewer (2): German-Israeli Foundation (2011) HRB Medical Charities Research Group (2008) IASLC (2011, 2012, 2013 on behalf of Professor Kenneth J. O'Byrne) INNOVATION FUND DENMARK (2015). Italian Telethon Foundation (2008) Multiple Sclerosis Society (UK) (2012) MRC Medical Research Council (2020) The Netherlands Organisation for Scientific Research (NWO) - VENI program (2013) National Science Centre Poland (OPUS) (2015, 2017) OeNB Anniversary Fund (Austria) (2014, 2015) OTKA - Hungarian Scientific Research Fund (2014, 2015) Prostate Cancer UK (2014) Prostate Cancer Research Centre (2019) Wellcome Trust (2009) Worldwide Cancer Research (2021) Swiss Cancer League (2010, 2018)
Ad Hoc Journal Reviewer for the following: Acta Neuropathologica, Aging, Antioxidants & Redox Signaling, BBA-Reviews on Cancer, BBA - Gene Regulatory Mechanisms, BioEssays, BMC Medical Genetics, BMC Urology, British Journal of Cancer, British Journal of Clinical Pharmacology, British Journal of Pharmacology, Cancer, Cancers (MDPI),Cancer Epidemiology, Cancer Immunology Research, Cancer Letters, Cancer Research, Clinical and Experimental Rheumatology, Cell Biochemistry and Biophysics, Cellular & Molecular Life Sciences, CNS & Neurological Disorders-Drug Targets (CNSND-DT), Clinical Cancer Research, Clinical Lung Cancer, Cytokine, Diabetologia, E-Biomedicine, Epigenetics, European Journal of Cell Biology, European Journal of Pharmacology, Experimental Cell Research, Expert Opinion On Investigational Drugs, Expert Opinion on Therapeutic Targets
Ad hoc reviewer for various journals (2): Future Oncology - Epigenomics, Frontiers in Systems Biology, Genes & Cancer, Genome Medicine, Hormone & Metabolic Research, Inflammation & Allergy - Drug Targets, International Journal of Cancer, International Journal of Immunogenetics, Irish Journal of Medical Science, Journal of Cellular & Molecular Medicine, Journal of Experimental and Molecular Pathology, Journal of Hematology & Oncology, The Journal of Pathology, Journal of Nucleic Acids, Journal of Thoracic Oncology, Life Sciences, Lung Cancer, Mini-Reviews in Medicinal Chemistry, Molecular Cancer Research, Molecular and Cancer Therapeutics, Molecular Therapy
Ad Hoc reviewer for the following journals (3): Neurogenetics, Neurological Research, Neuropsychiatric Disease and Treatment, the Open Diabetes Journal, Oncology Reports, OncoTarget, PLoS One, Pharmaceutical Patent Analyst, Pharmacological Research, Pharmacogenomics, Phytotherapy Research, Progress in Lipid Research, Stem Cells, Theranostics, Translational Research, Trends in Neurosciences, Trends in Molecular Medicine
Panel Member: The International Cancer Genome Consortium (workgroup: Renal Cancer)
Deputy Editor for the Epigenetic Regulators section of the Targeted Proteins database and Epigenetic Regulators section of the CBD Protein Systems journal (launched 2008)
Editorial Board Member The Open Diabetes Journal (Bentham http://www.bentham.org/open/todiaj/EBM.htm) from 2008
Founding Editorial Board Member "Clinical Epigenetics"
Member of the Editorial Academy for the "International Journal of Oncology" https://www.spandidos-publications.com/pages/ijo/editorial
Editorial Board member "World Journal of Experimental Medicine" (2011-2019)
Editorial Board member "Frontiers in Epigenomics" (Guest Associate Editor & Review Editor) http://www.frontiersin.org/Epigenomics
Editorial Board Member "Frontiers in Systems Physiology" (Review Editor, Systems Biology) http://www.frontiersin.org/systems_physiology
Editorial Board member World Journal of Biological Chemistry
Panel Member: The International Cancer Genome Consortium (workgroup: Renal Cancer)
Invited "ad hoc" contributor to Trends in Genetics Short In Brief Articles section
Independent Reporter for GenomeBiology (www.genomebiology.com)
Awards and Honours
Invited Speaker EFBIC Diabetes Workshop "Shifting paradigms in diabetes"
Memberships
British Thoracic Oncology Group
iMiG (International Mesothelioma Interest Group)
ETOP (European Thoracic Oncology Program) - www.etop-eu.org
ToPCaP (Transdisciplinary Prostate Cancer Partnership) - http://topcapteam.org/